PL2470191T3 - Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych - Google Patents

Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych

Info

Publication number
PL2470191T3
PL2470191T3 PL10812524T PL10812524T PL2470191T3 PL 2470191 T3 PL2470191 T3 PL 2470191T3 PL 10812524 T PL10812524 T PL 10812524T PL 10812524 T PL10812524 T PL 10812524T PL 2470191 T3 PL2470191 T3 PL 2470191T3
Authority
PL
Poland
Prior art keywords
compositions
treating
preventing
methods
ophthalmic condition
Prior art date
Application number
PL10812524T
Other languages
English (en)
Polish (pl)
Inventor
Liping Liu
Shibo Tang
Xiaoling Liang
Original Assignee
Stealth Peptides Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stealth Peptides Int Inc filed Critical Stealth Peptides Int Inc
Publication of PL2470191T3 publication Critical patent/PL2470191T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C07K5/0817—Tripeptides with the first amino acid being basic the first amino acid being Arg
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL10812524T 2009-08-24 2010-08-23 Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych PL2470191T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23644009P 2009-08-24 2009-08-24
US23774509P 2009-08-28 2009-08-28
US34847010P 2010-05-26 2010-05-26
EP10812524.6A EP2470191B1 (en) 2009-08-24 2010-08-23 Methods and compositions for preventing or treating ophthalmic conditions
PCT/US2010/046338 WO2011025734A1 (en) 2009-08-24 2010-08-23 Methods and compositions for preventing or treating ophthalmic conditions

Publications (1)

Publication Number Publication Date
PL2470191T3 true PL2470191T3 (pl) 2014-09-30

Family

ID=43628336

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10812524T PL2470191T3 (pl) 2009-08-24 2010-08-23 Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
PL20156769.0T PL3708178T3 (pl) 2009-08-24 2010-08-23 Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL20156769.0T PL3708178T3 (pl) 2009-08-24 2010-08-23 Peptyd do stosowania w zapobieganiu lub leczeniu zwyrodnienia plamki żółtej

Country Status (17)

Country Link
US (8) US8470784B2 (enExample)
EP (18) EP3150215A1 (enExample)
JP (7) JP6120399B2 (enExample)
CN (3) CN102625709A (enExample)
CA (1) CA2772094C (enExample)
DK (2) DK2470191T3 (enExample)
ES (3) ES2487633T3 (enExample)
FI (1) FI3708178T3 (enExample)
HK (4) HK1204958A1 (enExample)
HR (1) HRP20231277T1 (enExample)
HU (1) HUE064800T2 (enExample)
LT (1) LT3708178T (enExample)
PL (2) PL2470191T3 (enExample)
PT (2) PT2470191E (enExample)
SI (2) SI2470191T1 (enExample)
SM (1) SMT202300433T1 (enExample)
WO (1) WO2011025734A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8943434B2 (en) 2010-10-01 2015-01-27 Z124 Method and apparatus for showing stored window display
EP2367505B1 (en) 2008-09-29 2020-08-12 Edwards Lifesciences CardiAQ LLC Heart valve
EP2845569A1 (en) 2008-10-01 2015-03-11 Cardiaq Valve Technologies, Inc. Delivery system for vascular implant
WO2010121076A2 (en) 2009-04-15 2010-10-21 Cardiaq Valve Technologies, Inc. Vascular implant and delivery system
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
EP3560508A1 (en) * 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2563359A1 (en) * 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
SG187770A1 (en) 2010-08-12 2013-03-28 Univ Nanyang Tech A liposomal formulation for ocular drug delivery
EP3488941A1 (en) * 2011-03-24 2019-05-29 Cornell University Aromatic-cationic peptides and uses of same
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
CN102327600A (zh) * 2011-09-14 2012-01-25 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防和治疗辐射损伤的rx31肽
US20130076654A1 (en) 2011-09-27 2013-03-28 Imerj LLC Handset states and state diagrams: open, closed transitional and easel
EP2788013A4 (en) * 2011-12-09 2015-08-19 Stealth Peptides Int Inc AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
EP3078384A1 (en) * 2012-02-22 2016-10-12 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
EP3170506B1 (en) * 2012-03-30 2018-05-16 Stealth Peptides International, Inc. Methods and compositions for the prevention and treatment neuropathy
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
CN104661670A (zh) * 2012-08-02 2015-05-27 康肽德生物医药技术有限公司 用于治疗动脉粥样硬化的方法
US10330670B2 (en) 2012-10-24 2019-06-25 National University Corporation Tokyo University Of Agriculture And Technology Therapeutic or prophylactic agent for retinopathy of prematurity, testing method for retinopathy of prematurity, and screening method for therapeutic or prophylactic substance for retinopathy of prematurity
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
CN115990242A (zh) * 2013-03-01 2023-04-21 康德生物医疗有限公司 预防或治疗巴斯综合征的方法和组合物
CN117752766A (zh) * 2013-03-01 2024-03-26 康德生物医疗有限公司 治疗线粒体疾病的方法
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10583002B2 (en) 2013-03-11 2020-03-10 Neovasc Tiara Inc. Prosthetic valve with anti-pivoting mechanism
US9681951B2 (en) 2013-03-14 2017-06-20 Edwards Lifesciences Cardiaq Llc Prosthesis with outer skirt and anchors
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
WO2014209905A2 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods and compositions for detecting and diagnosing diseases and conditions
US20160193278A1 (en) * 2013-08-01 2016-07-07 Stealth Biotherapeutics Corp Methods and compositions for preventing or treating leber's hereditary optic neuropathy
US20160175379A1 (en) * 2013-08-12 2016-06-23 Stealth Bio Therapeutics Corp Combination therapy for the treatment of ischemia-reperfusion injury
AU2014339890A1 (en) * 2013-10-25 2016-06-02 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
EP3077049B1 (en) * 2013-12-02 2019-06-19 Stealth BioTherapeutics Corp Compositions for use in treating vitiligo
WO2015103577A1 (en) * 2014-01-06 2015-07-09 Stealth Peptides International, Inc. Methods and compositions for preventing or treating dominant optic atrophy
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
JP6692795B2 (ja) 2014-04-10 2020-05-13 ランケナー インスティテュート フォー メディカル リサーチ 眼疾患および眼障害の治療のための方法および組成物
US20170182117A1 (en) * 2014-05-28 2017-06-29 Stealth Biotherapeutics Corp Therapeutic compositions including therapeutic small molecules and uses thereof
EP3233174B1 (en) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
CN108697772B (zh) 2015-12-30 2022-06-24 马歇尔大学科研协会 用于治疗视网膜病的组合物和方法
CN109476700A (zh) 2016-03-11 2019-03-15 隐形生物治疗公司 结晶盐形式
SG11201808713YA (en) * 2016-04-11 2018-11-29 Univ Canberra Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
AU2017249218B2 (en) 2016-04-11 2020-08-27 Arcuate Therapeutics, Inc. Chiral peptides
US11034724B2 (en) 2017-04-05 2021-06-15 Stealth Biotherapeutics Corp. Crystalline salt forms of Boc-D-Arg-DMT-Lys-(Boc)-Phe-NH2
US20180318319A1 (en) 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
AU2018367909B2 (en) 2017-11-17 2022-03-10 Cellix Bio Private Limited Compositions and methods for the treatment of eye disorders
US10676506B2 (en) 2018-01-26 2020-06-09 Stealth Biotherapeutics Corp. Crystalline bis- and tris-hydrochloride salt of elamipretide
PL424452A1 (pl) * 2018-01-31 2019-08-12 Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
EP3787749A4 (en) * 2018-05-03 2022-01-26 Alimera Sciences, Inc. METHODS OF TREATMENT OF RETINAL DISEASES
US20210330735A1 (en) * 2018-07-16 2021-10-28 Stealth Biotherapeutics Corp Compositions and methods for the treatment of traumatic optic neuropathy
EP3852608A4 (en) * 2018-09-21 2022-09-28 Aufbau Medical Innovations Limited COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA
SG11202106716RA (en) * 2019-01-12 2021-07-29 Cellix Bio Private Ltd Combination of selective alpha-adrenergic receptor agonist or an anticholinergic agent and lipoic acid and uses thereof
JP2020174859A (ja) * 2019-04-17 2020-10-29 学校法人日本医科大学 網膜剥離が生じるリスクが低い網膜変性症（ｒｄ）モデルマウスを取得する方法
WO2020214990A1 (en) * 2019-04-17 2020-10-22 Ascidian Therapeutics, Inc. Abca4 cell line and methods of use
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
MX2021014555A (es) * 2019-05-28 2022-07-27 Elgan Pharma Ltd Composiciones y métodos de tratamiento de la retinopatía.
KR20230005177A (ko) * 2020-03-25 2023-01-09 아우프바우 메디컬 이노베이션스 리미티드 녹내장을 위한 방법 및 작용제
KR20230124625A (ko) * 2020-12-24 2023-08-25 산텐 세이야꾸 가부시키가이샤 에피나스틴 또는 그의 염과 황계 항산화제를 함유하는경피 투여용 의약 조성물
KR20240108412A (ko) * 2021-10-20 2024-07-09 스텔스 바이오테라퓨틱스 인코포레이티드 안과 병태를 치료하거나, 예방하거나, 억제하거나, 경감하거나 발병을 지연시키기 위한 방법 및 펩타이드 모방체를 포함하는 조성물
WO2023069255A1 (en) * 2021-10-20 2023-04-27 Stealth Biotherapeutics Inc. Methods and compositions comprising peptidomimitics for treating, preventing, inhibiting, ameliorating or delaying the onset of ophthalmic conditions
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
CN114099678A (zh) * 2021-11-23 2022-03-01 浙江大学 基于Keap1-Nrf2信号通路的晶状体损伤抑制剂
KR102662922B1 (ko) * 2022-05-31 2024-05-03 주식회사 세네릭스 신규의 d-아미노산 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5602100A (en) * 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
EP0350221B1 (en) * 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5674980A (en) * 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
EP0747092B1 (en) * 1995-06-09 2003-12-03 Hisamitsu Pharmaceutical Co., Inc. Matrix for iontophoresis
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) * 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
CA2329709A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
EP1218544B1 (en) * 1999-10-04 2009-06-03 The University of Medicine and Dentistry of New Jersey TAR RNA binding peptides
US6759520B1 (en) * 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) * 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
JP2001270832A (ja) * 2000-03-27 2001-10-02 Ito En Ltd 網膜障害予防剤
US7498297B2 (en) * 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) * 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
US7259180B2 (en) * 2002-08-14 2007-08-21 University Of Georgia Research Foundation, Inc. Methods and compositions for treatment of macular and retinal disease
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US20060172972A1 (en) 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
EP2865385B1 (en) * 2003-02-04 2016-11-16 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
JP2004323486A (ja) * 2003-04-30 2004-11-18 National Institute Of Advanced Industrial & Technology 網膜及び／又はブドウ膜疾患の予防乃至治療用点眼薬
ZA200509229B (en) * 2003-05-01 2007-03-28 Cornell Res Foundation Inc Method and carrier complexes for delivering molecules to cells
WO2005032481A2 (en) * 2003-09-30 2005-04-14 Scios Inc. Quinazoline derivatives as medicaments
CA2971928C (en) 2004-01-23 2019-01-08 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CA2562356A1 (en) 2004-04-08 2005-10-27 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
JP4760111B2 (ja) 2005-04-26 2011-08-31 株式会社セガ 映像オブジェクト表現用データ構造生成プログラム、映像オブジェクト表現用データ構造生成方法、映像ソフト開発装置、映像処理プログラム、映像処理方法、映像処理装置、映像オブジェクト表現用データ構造、および、記録媒体
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
JP2007043629A (ja) * 2005-06-30 2007-02-15 Sony Corp グラフィック・ユーザ・インタフェース装置と操作入力処理方法及び双方向コミュニケーション装置
WO2007011874A2 (en) 2005-07-15 2007-01-25 Chakshu Research Inc. Formulation and method for administration of ophthalmologically active agents
EP3260127B1 (en) * 2005-09-16 2019-05-01 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method of treating cerebral ischemia
JPWO2007043629A1 (ja) * 2005-10-05 2009-04-16 アキュメンバイオファーマ株式会社 エフリンｂ２を用いる血管新生の抑制方法
US20070259377A1 (en) * 2005-10-11 2007-11-08 Mickey Urdea Diabetes-associated markers and methods of use thereof
TW200744627A (en) 2006-02-21 2007-12-16 Pfizer Prod Inc Methods for the treatment of macular degeneration and related eye conditions
CA2648223A1 (en) * 2006-04-14 2007-10-25 Novartis Ag Use of il-i antibodies for treating ophthalmic disorders
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
DE102006042329B4 (de) * 2006-09-01 2008-08-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Verfahren zum selektiven plasmachemischen Trockenätzen von auf Oberflächen von Silicium-Wafern ausgebildetem Phosphorsilikatglas
WO2008073441A2 (en) 2006-12-11 2008-06-19 University Of Utah Research Foundation Compositions and methods for treating pathologic angiogenesis and vascular permeability
JP2008195655A (ja) * 2007-02-14 2008-08-28 Kitasato Institute 糖尿病白内障の治療剤
JP2008247898A (ja) * 2007-03-08 2008-10-16 Santen Pharmaceut Co Ltd トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
WO2008146721A1 (ja) 2007-05-25 2008-12-04 Santen Pharmaceutical Co., Ltd. 加齢黄斑変性の予防又は治療剤
PL2252312T3 (pl) * 2008-02-07 2014-10-31 Univ Cornell Sposoby zapobiegania lub leczenia insulinooporności
JP5677096B2 (ja) * 2008-02-26 2015-02-25 コーネル ユニヴァーシティー 急性腎障害を予防および治療するための方法
EP3563862B1 (en) 2009-03-20 2021-05-05 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
FR2945540B1 (fr) 2009-05-15 2012-06-08 Rhodia Operations Procede de preparation de mousse polyamide et mousse susceptible d'etre obtenue par ce procede
CN105031605A (zh) 2009-08-12 2015-11-11 康奈尔大学 预防或治疗代谢综合症的方法
EP3150215A1 (en) * 2009-08-24 2017-04-05 Stealth Peptides International, Inc. Methods and compositions for preventing or treating opthalmic conditions
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
WO2011106717A1 (en) * 2010-02-26 2011-09-01 University Of Florida Research Foundation, Inc. Mitochondrial-targeted antioxidants protect against mechanical ventilation-induced diaphragm dysfunction and skeletal muscle atrophy
EP3290433A1 (en) 2010-05-03 2018-03-07 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CN103764159A (zh) 2011-06-14 2014-04-30 康肽德生物医药技术有限公司 芳香族阳离子肽及其用途
CA2916492A1 (en) * 2013-06-27 2014-12-31 Stealth Biotherapeutics Corp Peptide therapeutics and methods for using same
US20160199437A1 (en) * 2015-01-08 2016-07-14 D. Travis Wilson Therapeutic compositions including iron chelators and uses thereof
US20160228491A1 (en) * 2015-02-09 2016-08-11 Stealth Biotherapeutics Corp Therapeutic compositions including phenazine-3-one and phenothiazine-3-one derivatives and uses thereof

Also Published As

Publication number Publication date
JP2023179733A (ja) 2023-12-19
CA2772094C (en) 2018-04-03
WO2011025734A1 (en) 2011-03-03
US11944662B2 (en) 2024-04-02
EP2470191A1 (en) 2012-07-04
EP2826487A1 (en) 2015-01-21
CA2772094A1 (en) 2011-03-03
US10188692B2 (en) 2019-01-29
EP4302829A3 (en) 2024-03-27
JP7642965B2 (ja) 2025-03-11
ES3036317T3 (en) 2025-09-17
US20230381264A1 (en) 2023-11-30
PL3708178T3 (pl) 2024-05-13
JP2017141306A (ja) 2017-08-17
SI3708178T1 (sl) 2024-01-31
EP3292868A1 (en) 2018-03-14
US8470784B2 (en) 2013-06-25
FI3708178T3 (fi) 2023-11-09
PT2470191E (pt) 2014-06-12
EP4596049A2 (en) 2025-08-06
EP2813235A1 (en) 2014-12-17
US20200061147A1 (en) 2020-02-27
US20140044689A1 (en) 2014-02-13
EP3124036A1 (en) 2017-02-01
EP3494983A1 (en) 2019-06-12
US11612633B2 (en) 2023-03-28
EP2470191B1 (en) 2014-05-07
US20160058825A1 (en) 2016-03-03
EP2957291A1 (en) 2015-12-23
EP4302829B1 (en) 2025-05-21
CN102625709A (zh) 2012-08-01
ES2487633T3 (es) 2014-08-22
US20210154259A1 (en) 2021-05-27
HK1247821A1 (zh) 2018-10-05
PT3708178T (pt) 2023-11-16
EP3318264A1 (en) 2018-05-09
EP3708178B1 (en) 2023-10-04
JP6332757B2 (ja) 2018-05-30
HK1204958A1 (en) 2015-12-11
EP2470191A4 (en) 2013-04-17
ES2964555T3 (es) 2024-04-08
EP2990049A1 (en) 2016-03-02
EP3338788A1 (en) 2018-06-27
CN107412722A (zh) 2017-12-01
US20170326197A1 (en) 2017-11-16
JP2020128431A (ja) 2020-08-27
DK3708178T3 (da) 2023-11-13
HRP20231277T1 (hr) 2024-02-02
EP3150215A1 (en) 2017-04-05
JP6381737B2 (ja) 2018-08-29
DK2470191T3 (da) 2014-07-07
JP2016026188A (ja) 2016-02-12
LT3708178T (lt) 2023-12-27
EP4596049A3 (en) 2025-08-13
HUE064800T2 (hu) 2024-04-28
HK1172833A1 (en) 2013-05-03
EP3524256A1 (en) 2019-08-14
US9023807B2 (en) 2015-05-05
EP3708178A1 (en) 2020-09-16
EP4302829A2 (en) 2024-01-10
JP2022001609A (ja) 2022-01-06
US9549963B2 (en) 2017-01-24
CN105056206A (zh) 2015-11-18
HK1206258A1 (en) 2016-01-08
EP3175862A1 (en) 2017-06-07
EP2962695A1 (en) 2016-01-06
JP2013502460A (ja) 2013-01-24
US20110177047A1 (en) 2011-07-21
JP6120399B2 (ja) 2017-04-26
SI2470191T1 (sl) 2014-08-29
SMT202300433T1 (it) 2024-01-10
EP3485896A1 (en) 2019-05-22
US20230346874A1 (en) 2023-11-02
HK1217900A1 (en) 2017-01-27
JP2018162329A (ja) 2018-10-18

Similar Documents

Publication Publication Date Title
PL2470191T3 (pl) Sposoby i kompozycje do profilaktyki lub leczenia stanów okulistycznych
EP2817018A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS
EP2608778A4 (en) COMPOSITIONS AND METHODS FOR TREATING BONE ANOMALIES
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
EP2579816A4 (en) Implant components and methods
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
IL202015A0 (en) Methods and compositions for treating skin conditions
BRPI1007477A2 (pt) método, e, composição de tratamento de poço
EP2655334A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
EP2496084A4 (en) COMPOSITIONS AND METHODS FOR TREATING COLITIS
IL215932A0 (en) Compositions and methods for treating burns
BR112013012485A2 (pt) método de tratamento com inibidor braf
EP2429584A4 (en) TREATMENT PROCEDURE AND COMPOSITIONS
BRPI1011325A2 (pt) composições e métodos para o tratamento de inflamação
EP2635282A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF MYELOFIBROSIS
BRPI1007929A2 (pt) "métodos e composições para o tratamento de neovascularização".
IL210097A0 (en) Compositions and methods for treating unfluenza
BRPI1013927A2 (pt) métodos e composições para o tratamento de lúpus
HUE063599T2 (hu) Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére
EP2590674A4 (en) COMPOSITIONS AND METHODS FOR INFLUENZA TREATMENT
EP2323579A4 (en) METHODS AND DEVICES FOR TREATING PRESBYOPIA
ZA201303222B (en) Composition and method for treating skin conditions
PL2632550T3 (pl) Sposoby i kompozycja do leczenia biegunki związanej z HIV
BRPI1016257A2 (pt) composições compreendendo finafloxacino e métodos para tratar infecções oftálmicas, ópticas ou nasais
BRPI1009141A2 (pt) composições e métodos para profilaxia e tratamento de vícios